Top Markets
#1 MON MON +2,759.42%
#2 $1 is all you need $1 is all you need +1,328.53%
#3 PYTHIA PYTHIA +44.53%
#4 eCash eCash +32.94%
#5 Siren Siren +24.14%
#6 Janction Janction +19.65%
#7 SAFEcoin SAFEcoin +17.31%
#8 PinGo PinGo +15.88%
#9 Velvet Velvet +15.84%
#10 Decred Decred +12.95%
Coin of the day
MON MON
Impostazioni
Lingua
ITALIANO
Valuta
USD
Tema
Sensorion SA Sensorion SA

Sensorion SA

ALSEN
Classifica tra le azioni #13314
Sensorion SA, a clinical-stage biopharmaceutical company, develops drug... Sensorion SA, a clinical-stage biopharmaceutical company, develops drug candidates for the treatment of inner ear disorders in France. The company develops OTOF-GT, a gene therapy development program to restore hearing in people living with Otoferlin deficiency; USHER-T1-GT, a gene therapy development program to for patients suffering from usher syndrome Type 1; and SENS-401, a drug candidate to treat sudden sensorineural hearing loss. Its pipeline also includes various products in development stage for restoring, treating, and preventing inner ear related disorders. The company has a collaboration agreement with Institut Pasteur for gene therapy program for pediatric and adult deafness; and with Sonova Holding AG to introduce genetic analysis for routine diagnosis of progressive hearing loss in adults through a combination of advanced therapeutic interventions and traditional hearing aids. Sensorion SA was founded in 2009 and is headquartered in Montpellier, France.
Prezzo delle azioni
$0.30780727
Capitalizzazione di mercato
$94.19M
Variazione (1 giorno)
-0.19%
Variazione (1 anno)
-34.73%
Paese
FR
Scambia Sensorion SA (ALSEN)

Categoria

Healthcare
Rapporto P/S per Sensorion SA (ALSEN)
Rapporto P/S al July 2026 TTM: 31.10
Secondo gli ultimi rapporti finanziari e il prezzo delle azioni di Sensorion SA, il rapporto P/S attuale (TTM) è 31.10. Alla fine del 2023, era pari a 10.07.
Storico del rapporto P/S per Sensorion SA da 2011 a 2026
Rapporto P/S alla fine di ogni anno
Anno Rapporto P/S Cambia
2026 (TTM) 31.10 14.55%
2024 27.15 169.61%
2023 10.07 68.16%
2022 5.99 -83.37%
2021 36.00 -7.10%
2020 38.75 504.07%
2019 6.41 24.60%
2018 5.15 -64.35%
2017 14.44 -99.23%
2016 1.87K 702.80%
2015 233.19 264.53%
2014 63.97 53.97%
2013 41.55 -35.02%
2012 63.94 -99.99%
2011 705.41K 0.00%
Rapporto P/S per aziende simili o concorrenti
Azienda Rapporto P/S Differenza del rapporto P/S Il paese
Novo Nordisk A/S Novo Nordisk A/S
Novo Nordisk A/S
NVO.US
4.26 -86.29%
DK
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
10.29 -66.92%
US
Regeneron Pharmaceuticals, Inc. Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
REGN.US
4.31 -86.16%
US
UCB SA UCB SA
UCB SA
UCB.BR
6.44 -79.28%
BE
Argenx SE Argenx SE
Argenx SE
ARGX.US
16.96 -45.47%
NL